The patent allowance extends CervoMed's IP runway for neflamapimod in DLB to 2042, but does not change the near-term clinical or financial trajectory. Monitor upcoming Phase 2/3 data readouts for neflamapimod; the stock's primary catalyst remains clinical results, not patent office actions.
Price Chart
Executive Summary
CervoMed Inc. received a USPTO notice of allowance for a new patent covering its drug candidate neflamapimod for the treatment of dementia with Lewy bodies in patients without substantial Alzheimer's tau pathology, providing IP protection expected into 2042. This is a non-financial, pipeline-protecting event for a pre-revenue clinical-stage biotech.
Key Facts
- USPTO notice of allowance received June 16, 2026
- Patent covers neflamapimod for dementia with Lewy bodies in patients without substantial Alzheimer's tau pathology
- Expected IP protection into 2042 (excluding potential patent term extension)
- No financial figures, revenue, or guidance provided in filing
Financial Impact
No financial impact disclosed; patent extends exclusivity for a niche DLB indication but does not alter near-term cash runway or revenue (company is pre-revenue).
Risk Factors
- Clinical trial failure for neflamapimod would render patent protection valueless
- No revenue or near-term approval path; company remains pre-commercial
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-021038 |
| Document: 0001437749-26-021038-index-headers.html | 0001437749-26-021038 |
| Document: 0001437749-26-021038-index.html | 0001437749-26-021038 |
| Document: 0001437749-26-021038.txt | 0001437749-26-021038 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | 8-K | $2.25 $2.24 | ▼ −0.44% | ▲ +0.66% | $2.22 (−1.33%) |
Oct 13, 2026 14d ago | 8-K | $2.27 $2.29 | ▲ +0.88% | ▲ +1.96% | $2.22 (−2.20%) |
Oct 9, 2026 18d ago | 8-K | $2.51 $2.27 | ▼ −9.56% | ▼ −9.55% | $2.22 (−11.55%) |
Sep 10, 2026 6w ago | Press Release | $2.48 $2.57 | ▲ +3.63% | ▲ +2.78% | $2.22 (−10.48%) |
Aug 10, 2026 11w ago | 8-K | $3.09 $3.07 | ▼ −0.65% | ▼ −0.90% | $2.22 (−28.16%) |
Aug 4, 2026 12w ago | 8-K | $2.80 $2.81 | ▲ +0.36% | ▲ +0.56% | $2.22 (−20.71%) |
Aug 4, 2026 12w ago | Press Release | $2.80 $2.81 | ▲ +0.36% | ▲ +0.56% | $2.22 (−20.71%) |
Jul 13, 2026 15w ago | EFFECT | $3.31 $3.08 | ▲ +6.95% | ▲ +7.30% | $2.22 (+32.93%) |
Jul 6, 2026 16w ago | S-3 | $3.42 $3.41 | ▲ +0.29% | ▼ −0.02% | $2.22 (+35.09%) |
Jun 22, 2026 18w ago | 8-K | $3.72 $3.26 | ▲ +12.37% | ▲ +12.32% | $2.22 (+40.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers